In agreement with the existing evidence, treating whole blood of patients with cancer with IL-2, IL-15 and IL-21 markedly improved the antigen-specific IFNγ response regardless of existing immunosuppression, thereby suggesting clinical applicability. The gene discussed is IL15; the disease is cancer.